-
1
-
-
0026035891
-
Initial therapy of Wilson's disease patients with tetrathiomolybdate
-
Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, Tankanow R, Young AB, Kluin KJ. Initial therapy of Wilson's disease patients with tetrathiomolybdate. Arch Neurol 48:42-47, 1991.
-
(1991)
Arch Neurol
, vol.48
, pp. 42-47
-
-
Brewer, G.J.1
Dick, R.D.2
Yuzbasiyan-Gurkan, V.3
Tankanow, R.4
Young, A.B.5
Kluin, K.J.6
-
2
-
-
0037337399
-
Treatment of Wilson's disease with tetrathiomolybdate III: Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy
-
Brewer GJ, Hedera P, Kluin KJ, Carlson MD, Askari F, Dick RB, Sitterly JA, Fink JK. Treatment of Wilson's disease with tetrathiomolybdate III: initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 60:378-385, 2003.
-
(2003)
Arch Neurol
, vol.60
, pp. 378-385
-
-
Brewer, G.J.1
Hedera, P.2
Kluin, K.J.3
Carlson, M.D.4
Askari, F.5
Dick, R.B.6
Sitterly, J.A.7
Fink, J.K.8
-
3
-
-
0036733754
-
Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis
-
Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, De Carvalho M, Mesri EA, Robins DM, Dick RD, Brewer GJ, Merajver SD. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 62:4854-4859, 2002.
-
(2002)
Cancer Res
, vol.62
, pp. 4854-4859
-
-
Pan, Q.1
Kleer, C.G.2
Van Golen, K.L.3
Irani, J.4
Bottema, K.M.5
Bias, C.6
De Carvalho, M.7
Mesri, E.A.8
Robins, D.M.9
Dick, R.D.10
Brewer, G.J.11
Merajver, S.D.12
-
4
-
-
0035073521
-
The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma
-
Cox CD, Teknos TN, Barrios M, Brewer GJ, Dick RD, Merajver SD. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope 111:696-701, 2001.
-
(2001)
Laryngoscope
, vol.111
, pp. 696-701
-
-
Cox, C.D.1
Teknos, T.N.2
Barrios, M.3
Brewer, G.J.4
Dick, R.D.5
Merajver, S.D.6
-
5
-
-
0036118349
-
Radiotherapy and antiangiogenic TM in lung cancer
-
Khan MK, Miller MW, Taylor J, Gill NK, Dick RD, van Golen K, Brewer GJ, Merajver SD. Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia 4:1-7, 2002.
-
(2002)
Neoplasia
, vol.4
, pp. 1-7
-
-
Khan, M.K.1
Miller, M.W.2
Taylor, J.3
Gill, N.K.4
Dick, R.D.5
Van Golen, K.6
Brewer, G.J.7
Merajver, S.D.8
-
6
-
-
0036708501
-
Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma
-
van Golen K, Bao L, Brewer G, Pienta K, Karadt J, Livant D, Merajver S. Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma. Neoplasia 4:373-379, 2002.
-
(2002)
Neoplasia
, vol.4
, pp. 373-379
-
-
Van Golen, K.1
Bao, L.2
Brewer, G.3
Pienta, K.4
Karadt, J.5
Livant, D.6
Merajver, S.7
-
7
-
-
1642499579
-
An anticopper antiangiogenic approach for advanced cancer in spontaneously occurring tumors, using tetrathiomolybdate: A pilot study in a canine animal model
-
Kent MS, Madewell BR, Dank G, Dick R, Merajver SD, Brewer GJ. An anticopper antiangiogenic approach for advanced cancer in spontaneously occurring tumors, using tetrathiomolybdate: a pilot study in a canine animal model. J Trace Elem Exp Med 17:9-20, 2004.
-
(2004)
J Trace Elem Exp Med
, vol.17
, pp. 9-20
-
-
Kent, M.S.1
Madewell, B.R.2
Dank, G.3
Dick, R.4
Merajver, S.D.5
Brewer, G.J.6
-
8
-
-
0033963879
-
Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent, I: Phase I study
-
Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Thierry J, Sondak VK, Strawderman M, LeCarpentier G, Merajver SD. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent, I: phase I study. Clin Cancer Res 6:1-10, 2000.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 1-10
-
-
Brewer, G.J.1
Dick, R.D.2
Grover, D.K.3
LeClaire, V.4
Tseng, M.5
Wicha, M.6
Pienta, K.7
Redman, B.G.8
Thierry, J.9
Sondak, V.K.10
Strawderman, M.11
LeCarpentier, G.12
Merajver, S.D.13
-
9
-
-
0034937998
-
Copper control as an antiangiogenic anticancer therapy: Lessons from treating Wilson's disease
-
Brewer GJ. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp Biol Med 226:665-673, 2001.
-
(2001)
Exp Biol Med
, vol.226
, pp. 665-673
-
-
Brewer, G.J.1
-
10
-
-
0141799951
-
Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis, and inflammation
-
Brewer GJ. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis, and inflammation. J Cell Mol Med 7:11-20, 2003.
-
(2003)
J Cell Mol Med
, vol.7
, pp. 11-20
-
-
Brewer, G.J.1
-
11
-
-
0037399007
-
Copper in medicine
-
Brewer GJ. Copper in medicine. Curr Opin Chem Biol 7:207-212, 2003.
-
(2003)
Curr Opin Chem Biol
, vol.7
, pp. 207-212
-
-
Brewer, G.J.1
-
12
-
-
0018342680
-
Copper regulation of ceruloplasmin in copper-deficient rats
-
Linder MC, Houle PA, Isaacs E, Moor JR, Scott LE. Copper regulation of ceruloplasmin in copper-deficient rats. Enzyme 24:23-35, 1979.
-
(1979)
Enzyme
, vol.24
, pp. 23-35
-
-
Linder, M.C.1
Houle, P.A.2
Isaacs, E.3
Moor, J.R.4
Scott, L.E.5
-
13
-
-
0028109801
-
Transforming growth factor beta in tissue fibrosis
-
Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 331:1286-1292, 1994.
-
(1994)
N Engl J Med
, vol.331
, pp. 1286-1292
-
-
Border, W.A.1
Noble, N.A.2
-
14
-
-
0032873465
-
Connective tissue growth factor mediates transforming growth factor β-induced collagen synthesis: Down-regulation by cAMP
-
Duncan MR, Frazier KS, Abramson S, Williams S, Klapper H, Huang X, Grotendorst GR. Connective tissue growth factor mediates transforming growth factor β-induced collagen synthesis: down-regulation by cAMP. FASEB J 13:1774-1786, 1999.
-
(1999)
FASEB J
, vol.13
, pp. 1774-1786
-
-
Duncan, M.R.1
Frazier, K.S.2
Abramson, S.3
Williams, S.4
Klapper, H.5
Huang, X.6
Grotendorst, G.R.7
-
15
-
-
0026597574
-
Lung cytokine production in bleomycin-induced pulmonary fibrosis
-
Phan SH, Kunkel SL. Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp Lung Res 18:29-43, 1992.
-
(1992)
Exp Lung Res
, vol.18
, pp. 29-43
-
-
Phan, S.H.1
Kunkel, S.L.2
-
16
-
-
0032787927
-
The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family
-
Brigstock DR. The connective tissue growth factor/cysteine-rich 61/ nephroblastoma overexpressed (CCN) family. Endocr Rev 20:189-206, 1999.
-
(1999)
Endocr Rev
, vol.20
, pp. 189-206
-
-
Brigstock, D.R.1
-
17
-
-
0013241440
-
Tetrathiomolybdate anticopper therapy protects against bleomycin-pulmonary fibrosis in mice
-
Brewer GJ, Phan S. Tetrathiomolybdate anticopper therapy protects against bleomycin-pulmonary fibrosis in mice. J Invest Med 50:227A, 2002.
-
(2002)
J Invest Med
, vol.50
-
-
Brewer, G.J.1
Phan, S.2
-
18
-
-
0037342259
-
Tetrathiomolybdate therapy protects against bleomycin-pulmonary fibrosis in mice
-
Brewer GJ, Ullenbruch MR, Dick R, Olivarez L, Phan SH. Tetrathiomolybdate therapy protects against bleomycin-pulmonary fibrosis in mice. J Lab Clin Med 141:210-216, 2003.
-
(2003)
J Lab Clin Med
, vol.141
, pp. 210-216
-
-
Brewer, G.J.1
Ullenbruch, M.R.2
Dick, R.3
Olivarez, L.4
Phan, S.H.5
-
19
-
-
0034869412
-
Macrophage inflammatory protein-2 induced by TNF-α plays a pivotal role in concanavalin A-induced liver injury in mice
-
Nakamura K, Okada M, Yoneda M, Takamoto S, Nakade Y, Tamori K, Aso K, Makino I. Macrophage inflammatory protein-2 induced by TNF-α plays a pivotal role in concanavalin A-induced liver injury in mice. J Hepatol 35:217-224, 2001.
-
(2001)
J Hepatol
, vol.35
, pp. 217-224
-
-
Nakamura, K.1
Okada, M.2
Yoneda, M.3
Takamoto, S.4
Nakade, Y.5
Tamori, K.6
Aso, K.7
Makino, I.8
-
20
-
-
0035675083
-
The role of tumor necrosis factor-α in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride
-
Simeonova PP, Gallucci RM, Hulderman T, Wilson R, Kommineni C, Rao M, Luster MI. The role of tumor necrosis factor-α in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride. Toxicol Appl Pharmacol 177:112-120, 2001.
-
(2001)
Toxicol Appl Pharmacol
, vol.177
, pp. 112-120
-
-
Simeonova, P.P.1
Gallucci, R.M.2
Hulderman, T.3
Wilson, R.4
Kommineni, C.5
Rao, M.6
Luster, M.I.7
-
22
-
-
0027438710
-
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF-α
-
Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF-α. Arthritis Rheum 36:1681-1690, 1993.
-
(1993)
Arthritis Rheum
, vol.36
, pp. 1681-1690
-
-
Elliott, M.J.1
Maini, R.N.2
Feldmann, M.3
Long-Fox, A.4
Charles, P.5
Katsikis, P.6
Brennan, F.M.7
Walker, J.8
Bijl, H.9
Ghrayeb, J.10
Woody, J.N.11
-
23
-
-
0036594572
-
Tumor necrosis factor-α blockade: A novel therapy for rheumatic disease
-
Shanahan CS, St. Clair EW. Tumor necrosis factor-α blockade: a novel therapy for rheumatic disease. Clin Immunol 103:231-242, 2002.
-
(2002)
Clin Immunol
, vol.103
, pp. 231-242
-
-
Shanahan, C.S.1
St. Clair, E.W.2
-
24
-
-
0033529049
-
Infliximab for the treatment of fistulas in patients with Crohn's disease
-
Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:1398-1405, 1999.
-
(1999)
N Engl J Med
, vol.340
, pp. 1398-1405
-
-
Present, D.H.1
Rutgeerts, P.2
Targan, S.3
Hanauer, S.B.4
Mayer, L.5
Van Hogezand, R.A.6
Podolsky, D.K.7
Sands, B.E.8
Braakman, T.9
DeWoody, K.L.10
Schaible, T.F.11
Van Deventer, S.J.12
-
25
-
-
0032913394
-
Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multi-center trial
-
D'haens G, Van Deventer S, van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multi-center trial. Gastroenterology 116:1029-1034, 1999.
-
(1999)
Gastroenterology
, vol.116
, pp. 1029-1034
-
-
D'haens, G.1
Van Deventer, S.2
Van Hogezand, R.3
Chalmers, D.4
Kothe, C.5
Baert, F.6
Braakman, T.7
Schaible, T.8
Geboes, K.9
Rutgeerts, P.10
-
26
-
-
0035083651
-
Treatment of psoriatic arthritis with anti-tumor necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate
-
Ogilvie AL, Atoni C, Dechant C, Manger B, Kalden JR, Schuler G, Luftl M. Treatment of psoriatic arthritis with anti-tumor necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 144:587-589, 2001.
-
(2001)
Br J Dermatol
, vol.144
, pp. 587-589
-
-
Ogilvie, A.L.1
Atoni, C.2
Dechant, C.3
Manger, B.4
Kalden, J.R.5
Schuler, G.6
Luftl, M.7
-
27
-
-
0035832515
-
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomized trial
-
Chaudhari U, Roman P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 357:1842-1847, 2001.
-
(2001)
Lancet
, vol.357
, pp. 1842-1847
-
-
Chaudhari, U.1
Roman, P.2
Mulcahy, L.D.3
Dooley, L.T.4
Baker, D.G.5
Gottlieb, A.B.6
-
28
-
-
0034729950
-
Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial
-
Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 35:385-390, 2000.
-
(2000)
Lancet
, vol.35
, pp. 385-390
-
-
Mease, P.J.1
Goffe, B.S.2
Metz, J.3
VanderStoep, A.4
Finck, B.5
Burge, D.J.6
-
30
-
-
0034101822
-
Loss of TGF-β signaling contributes to autoimmune pancreatitis
-
Hahm KB, Im YH, Lee C, Parks WT, Bang YJ, Green JE, Kim SJ. Loss of TGF-β signaling contributes to autoimmune pancreatitis. J Clin Invest 105:1057-1065, 2000.
-
(2000)
J Clin Invest
, vol.105
, pp. 1057-1065
-
-
Hahm, K.B.1
Im, Y.H.2
Lee, C.3
Parks, W.T.4
Bang, Y.J.5
Green, J.E.6
Kim, S.J.7
-
31
-
-
0036987742
-
Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration
-
Vine AK, Brewer GJ. Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Trans Am Ophthalmol Soc 100:73-76, 2002.
-
(2002)
Trans Am Ophthalmol Soc
, vol.100
, pp. 73-76
-
-
Vine, A.K.1
Brewer, G.J.2
-
32
-
-
0037652214
-
Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer
-
Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ, Merajver SD. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 9:1666-1672, 2003.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 1666-1672
-
-
Redman, B.G.1
Esper, P.2
Pan, Q.3
Dunn, R.L.4
Hussain, H.K.5
Chenevert, T.6
Brewer, G.J.7
Merajver, S.D.8
|